Recurrent optic neuritis as the first presentation of monoclonal gammopathy of undetermined significance: a case report Authors: Ahmad Pourmohammadi, Saba Naghavi, Iman Adibi Published: 2026 ABSTRACT BackgroundMonoclonal gammopathy of undetermined significance (MGUS), which can be asymptomatic, is a premalignant proliferative disorder of plasma cells. The peripheral nervous system may be involved in MGUS, causing a monoclonal gammopathy associated peripheral neuropathy. However, involvement of the central nervous system (CNS) in MGUS was rarely reported.Case presentationHere we report a rare case of recurrent optic neuritis, as the first clinical presentation of MGUS, in an otherwise healthy 54-year-old Iranian male patient. He was treated with intravenous high-dose methylprednisolone for acute attacks and rituximab as maintenance therapy. The patient’s vision recovered, and he did not experience any other attack in 2 years of follow-up.ConclusionThis case demonstrates that MGUS should be considered in the differential diagnosis of recurrent optic neuritis, expanding the spectrum of CNS involvement associated with this condition. The favorable response to immunotherapy suggests a possible immune-mediated mechanism. Background Monoclonal gammopathy of undetermined significance (MGUS), which can be asymptomatic, is a premalignant proliferative disorder of plasma cells. It is defined by the presence of serum monoclonal immunoglobulin < 3 g/dL, plasma cells in the bone marrow < 10%, and absence of end-organ damage. There are three distinct types of MGUS based on the involved immunoglobulin: non-IgM, IgM, and light-chain, each with a risk of progression to a malignant plasma cell dyscrasia or lymphoproliferative disorder. It is not rare for MGUS to be an incidental finding, but it can be correlated with shorter life expectancy even in the absence of malignancy [1]. Previous studies showed some associations between MGUS and increased fracture risk, renal impairment, secondary immunodeficiency, infections, thromboembolism, and cardiovascular diseases. The peripheral nervous system may be involved in MGUS, causing a monoclonal gammopathy associated peripheral neuropathy [2, 3]. However, involvement of the central nervous system (CNS) in MGUS was rarely reported. Here we report a rare case of recurrent optic neuritis, as the first clinical presentation of MGUS, in an otherwise healthy male patient. Case presentation A 54-year-old male Iranian patient was presented to the neurology clinic with a headache and blurred vision in his left eye. The patient’s symptoms had begun following psychological stress. Headache was generalized and oppressive in nature and blurred vision was progressive and accompanied by eye pain. The patient’s medical history revealed LASIK eye surgery performed 4 months ago for hyperopia, after which his visual acuity was normal (10/10). He denied experiencing similar symptoms in the past. There were no neurological symptoms suggestive of multiple sclerosis (MS) or neuromyelitis optica (NMO). He also denied any history of neurological disorders, including MS or NMO, and had no other significant medical history. In addition, there was no recent history of viral illness, recent vaccination, or other medical conditions. On clinical examination, the patient had decreased visual acuity in the left eye, measured at 4/10. A relative afferent pupillary defect (RAPD) was present in the left eye. Eye movements were painful but showed no restrictions (other examinations shown in Table 1). The patient did not report any worsening of vision with increased body temperature or exertion. Motion and depth perception could not be reliably assessed due to decreased visual acuity, he had mild dyschromatopsia (80% red desaturation in the left eye). The cranial nerve examination was otherwise unremarkable, with no deficits observed in other cranial nerves. There were no sensory or motor symptoms, and no focal neurological deficits were noted. Table 1Examination findingsLeftRightVisual acuity (Snellen)4/1010/10Anterior segmentNormalNormalIntraocular pressure15 mmHg15 mmHgPupilsGrade 2 RAPDBriskIshihara15/1515/15Extraocular movementFullFullVisual fieldNasal defectFullRed saturation80% all quadrants100%Light brightness60%100%FundusDisk swelling without peripapillary hemorrhages0.3 pink disc Table 1Examination findingsLeftRightVisual acuity (Snellen)4/1010/10Anterior segmentNormalNormalIntraocular pressure15 mmHg15 mmHgPupilsGrade 2 RAPDBriskIshihara15/1515/15Extraocular movementFullFullVisual fieldNasal defectFullRed saturation80% all quadrants100%Light brightness60%100%FundusDisk swelling without peripapillary hemorrhages0.3 pink disc Examination findings Magnetic resonance imaging (MRI) of the brain and cervical spine and positron emission tomography (PET) scans were normal. Increased latency of visual-evoked potentials (VEPs) was found after stimulation of the left eye. All performed blood investigations and vasculitis panels were normal. Thyroid stimulating hormone (TSH) was 1.7 mU/L (normal range 0.55–4.78 mU/L) and angiotensin-converting enzyme (ACE) was 48 U/L (normal range 13.3–63.9 U/L). Cell-based antibody assays for anti-aquaporin-4 antibody (AQP4-Ab) and antibody against myelin oligodendrocyte glycoprotein (anti-MOG-Ab) were also reported negative. The patient underwent a diagnostic lumbar puncture which determined a normal opening pressure of cerebrospinal fluid (CSF). CSF examination showed albumin 28.2 mg/dl (normal values < 30 mg/dl), IgG index 1.43 (normal values < 0.65), no pleocytosis and no elevated protein level. The oligoclonal band assay detected no heterologous band in CSF. Given the patient’s history of prior eye surgery, ischemic optic neuropathy was considered in the differential diagnosis. However, while recent LASIK raised a theoretical consideration for non-arteritic anterior ischemic optic neuropathy (NAION), the presence of pain, rapid improvement with corticosteroids, and absence of a classic altitudinal visual field defect supported optic neuritis as the more likely diagnosis. The clinical timeline of this case is summarized in Fig. 1. The patient was subsequently treated with 3 days of intravenous high-dose methylprednisolone (1000 mg daily). After receiving corticosteroid, the patient's vision improved significantly. The rapid response to steroids further supports the diagnosis of optic neuritis more than ischemic neuropathy. We performed serum protein electrophoresis and immunofixation for further investigation. Serum protein electrophoresis revealed a peak in the gamma-globulin region. Serum Fractions levels were as follows: albumin 4.8 g/dl (4–4.8 g/dl), alpha-1 0.2 g/dl (0.2–0.4 g/dl), alpha-2 0.6 g/dl (0.5–0.9 g/dl), beta-1 0.4 g/dl (0.3–0.5 g/dl), beta-2 0.3 g/dl (0.2–0.5 g/dl), and gamma 1.6 g/dl (0.8–1.4 g/dl). In immunofixation, the gamma-globulin band was highlighted in Kappa and IgG region that is compatible with monoclonal Kappa IgG (Fig. 2). A bone marrow aspiration (BMA) and biopsy (BMB) showed the presence of normocellular marrow with trilineage hematopoiesis and 6–7% polyclonal plasma cells. IHC staining showed CD138, Kappa, Lambda, and Pax5 positive. This result confirms the plasma cell origin, monoclonality, and highlights the B-cell lineage of the plasma cells involved. BMA immunophenotyping revealed a population in monocytic gates which express CD138, CD38, negative CD19, CD45 (myeloma cell) about 1–1.5% of all nucleated cells (Table 2). There was no increase in myeloblast and B-lymphoblast. There was no clinical manifestation associated with plasma cell myeloma such as lytic bone lesions, and the amount of monoclonal component was < 3 g/dl. According to these results, he was diagnosed with optic neuritis with MGUS, in accordance with the updated criteria of the International Myeloma Working Group [4].Fig. 1Clinical timeline of the case. Sequence of clinical events and treatments, including the first episode of optic neuritis, intravenous high-dose methylprednisolone therapy, rituximab induction, relapse with contralateral optic neuritis, repeat steroid treatment, and subsequent maintenance rituximab with sustained clinical stability over 2 years of follow-upFig. 2Serum immunofixation electrophoresis. Lanes correspond to ELP, IgG (G), IgA (A), IgM (M), κ (Kappa), and λ (Lambda). Immunofixation demonstrates a discrete monoclonal band in the gamma region, identified as IgG-κ (kappa), compatible with monoclonal Kappa IgGTable 2Bone marrow aspirate and biopsy immunophenotypingMarkerCell populationPositive cells (%)CD138Plasma cells6CD38Plasma cells23CD38/CD138Plasma cells6CD19B cells6CD22B cells6.2CD23B cells0.2CD3T cells18.5CD33Monocytes/granulocytes0.4CD13Monocytes/granulocytes0.1CD64Monocytes0.5CD117Myeloid progenitors3.7CD34Hematopoietic progenitors1.5CD45Leukocytes34CD45/CD19B cells3.8CD19−/CD138+/CD45−Aberrant plasma cells5 Clinical timeline of the case. Sequence of clinical events and treatments, including the first episode of optic neuritis, intravenous high-dose methylprednisolone therapy, rituximab induction, relapse with contralateral optic neuritis, repeat steroid treatment, and subsequent maintenance rituximab with sustained clinical stability over 2 years of follow-up Serum immunofixation electrophoresis. Lanes correspond to ELP, IgG (G), IgA (A), IgM (M), κ (Kappa), and λ (Lambda). Immunofixation demonstrates a discrete monoclonal band in the gamma region, identified as IgG-κ (kappa), compatible with monoclonal Kappa IgG Table 2Bone marrow aspirate and biopsy immunophenotypingMarkerCell populationPositive cells (%)CD138Plasma cells6CD38Plasma cells23CD38/CD138Plasma cells6CD19B cells6CD22B cells6.2CD23B cells0.2CD3T cells18.5CD33Monocytes/granulocytes0.4CD13Monocytes/granulocytes0.1CD64Monocytes0.5CD117Myeloid progenitors3.7CD34Hematopoietic progenitors1.5CD45Leukocytes34CD45/CD19B cells3.8CD19−/CD138+/CD45−Aberrant plasma cells5 Bone marrow aspirate and biopsy immunophenotyping The patient initially received intravenous high-dose methylprednisolone (1000 mg daily for 3 days), which resulted in an improvement in visual acuity and a reduction in symptoms. Given the association with MGUS and the recurrent nature of optic neuritis in this patient, a maintenance therapy regimen with Rituximab was initiated. The patient received two intravenous infusions of 500 mg Rituximab, two weeks apart, as part of the induction therapy. However, within 1 week of the Rituximab induction, the patient experienced a relapse with a new optic neuritis attack in the fellow eye. To address this acute relapse, intravenous high-dose methylprednisolone therapy was again administered (1000 mg daily for 3 days), Following this treatment, rituximab was continued as part of the maintenance regimen. The patient received rituximab every 6 months, guided by CD19 flow cytometry results to assess B-cell depletion. After 2 years of starting rituximab therapy, the patient remained stable with no new symptoms or relapses. This treatment approach was well-tolerated, and the patient’s vision remained stable. At follow-up evaluations conducted at 6 months and 2 years, clinical and laboratory assessments revealed no evidence of progression to malignant conditions. The serum-free light-chain ratio remained within the normal range, and the serum M protein level was consistently below 1.5 g/dL. Discussion Neurologic complications of MGUS are uncommon and are classically described in the peripheral nervous system, most notably in association with demyelinating neuropathies such as anti-MAG neuropathy. In these cases, monoclonal IgM antibodies directed against myelin-associated glycoprotein (MAG) are believed to mediate immune-related myelin injury. Given that MAG is expressed in both the central and peripheral nervous systems, CNS involvement in MGUS has been hypothesized to arise through similar antibody-mediated mechanisms. Indeed, subclinical optic pathway abnormalities, including prolonged visual evoked potential (VEP) latencies, have been reported in MGUS patients with anti-MAG antibodies [5]. Beyond subclinical findings, overt CNS manifestations associated with MGUS have been described, including demyelinating syndromes resembling multiple sclerosis (MS) [6], acute disseminated encephalomyelitis (ADEM) [6], and neuromyelitis optica spectrum disorders (NMOSD) [7]. Additional CNS associations described in MGUS include cerebellar atrophy [8], Parkinson's disease [9], and multiple system atrophy [9]. However, optic neuritis as the sole clinical presentation of MGUS remains exceptionally rare. Our case therefore expands the spectrum of potential CNS involvement in MGUS. The mechanism linking MGUS to recurrent optic neuritis remains unclear. Insights from previously reported CNS involvement of MGUS, including MS, may help inform potential pathophysiological mechanisms. Monoclonal IgM/λ gammopathy with anti-myelin and anti-nuclear reactivity [10], as well as IgG/λ monoclonal gammopathy [11], have been described in association with CNS demyelination. One potential explanation is an antibody-mediated process. Although anti-AQP4 and anti-MOG antibodies were negative, MGUS-related neurologic injury may involve other, less commonly tested autoantibodies directed against myelin or neuronal antigens. Monoclonal proteins themselves may exert pathogenic effects through direct immune reactivity, such as complement activation or immune complex deposition. Alternatively, the optic neuritis may represent a paraneoplastic-like autoimmune phenomenon driven by the underlying B-cell clone. The detection of PAX5 positivity, a marker of B-cell lineage, supports the presence of a clonal B-cell population but does not establish pathogenicity. In this case, rituximab was selected as maintenance therapy based on the recurrent nature of the optic neuritis and the availability of therapeutic resources in our country. An important clinical feature of our case was the relapse of optic neuritis in the contralateral eye occurring within one week of initiating rituximab induction therapy. Early relapses after rituximab initiation have been reported in neuroimmune disorders [12, 13] and do not necessarily indicate treatment failure. The rapid response to corticosteroid therapy and subsequent clinical stability during maintenance rituximab support the interpretation that this episode was unlikely to represent true rituximab failure. Instead, it may reflect ongoing immune-mediated pathology during the window preceding effective B-cell depletion. Although optic neuritis associated with MGUS is rare and robust evidence supporting rituximab efficacy in this context is limited, the clinical response in our patient was favorable, with no further relapses and sustained stability over 2 years of follow-up. A critical question is whether the optic neuritis should be attributed to MGUS or considered idiopathic with incidental MGUS. Although causality cannot be definitively established based on a single case, the potential for CNS involvement in MGUS is clinically important and warrants further investigation. Conclusions This case highlights that MGUS may rarely be associated with isolated recurrent optic neuritis. MGUS should be considered in the differential diagnosis of recurrent optic neuritis when common demyelinating etiologies have been excluded. The patient’s favorable response to corticosteroids and sustained clinical stability with rituximab suggest a possible immune-mediated mechanism. Further studies are needed to clarify the relationship between MGUS and CNS inflammation and to guide optimal treatment strategies.